Nuvalent Announces $500M Class A Common Stock Offering

Author: Benzinga Newsdesk | November 17, 2025 04:02pm

Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that it has commenced an underwritten public offering of shares of Class A common stock. Nuvalent is offering $500.0 million of shares in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund IV, L.P. (together, the "Selling Stockholders") expect to grant the underwriters a 30-day option to purchase from the Selling Stockholders up to an additional 15% of the shares of Class A common stock sold in the public offering at the public offering price less underwriting discounts and commissions. Nuvalent will not receive any proceeds from any sale of shares by the Selling Stockholders.

Posted In: NUVL